crovalimab
Selected indexed studies
- Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. (Am J Hematol, 2024) [PMID:38884175]
- Crovalimab: First Approval. (Drugs, 2024) [PMID:38740735]
- Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. (Am J Hematol, 2024) [PMID:38924124]
_Worker-drafted node — pending editorial review._
Connections
crovalimab is a side effect of
Sources
- Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. (2024) pubmed
- Crovalimab: First Approval. (2024) pubmed
- Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria. (2024) pubmed
- Crovalimab-akkz. (2024) pubmed
- Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape. (2024) pubmed
- The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. (2020) pubmed
- PMID:39869751 (2024) pubmed
- Advancements in PNH treatment: crovalimab's clinical efficacy. (2024) pubmed
- Crovalimab: a new era in paroxysmal nocturnal hemoglobinuria management. (2025) pubmed
- Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment. (2024) pubmed